How did 60 Degrees Pharmaceuticals (SXTP) change the reported affiliate share count?

The affiliate’s beneficial ownership was previously disclosed as 21,490 shares. The company now states the correct number is 23,367 shares, updating the prior disclosure to reflect the accurate position attributed to that affiliate.

How does the reverse stock split affect the corrected share numbers for SXTP’s affiliate?

After giving effect to a 1-for-4 reverse stock split, the corrected total number of shares beneficially owned by the affiliate is 16,781, instead of the previously reported 15,905 shares, aligning split-adjusted figures with the accurate underlying ownership.

Affiliate share ownership restated by 60 Degrees (NASDAQ: SXTP)

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

60 Degrees Pharmaceuticals, Inc. filed a Form 8-K to correct an error in previously disclosed share ownership for a company affiliate. A March 13, 2026 prospectus supplement had shown the affiliate as beneficially owning 21,490 shares; the correct figure is 23,367 shares. The error traces back to an incorrect total in a Form 4 dated September 15, 2025 that was carried into a December 16, 2025 Form 4 and then into the prospectus disclosure. After giving effect to the 1-for-4 reverse stock split, the corrected total number of shares beneficially owned is 16,781 instead of 15,905. The company states that no other information in the prospectus supplement is affected.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Understanding 8-K Material Events →

03/20/2026 - 04:15 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 20, 2026

60 DEGREES PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41719		45-2406880
(State or other jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification Number)

1025 Connecticut Avenue NW Suite 1000, Washington, D.C.		20036
(Address of registrant’s principal executive office)		(Zip code)

(202) 327-5422

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	SXTP	The Nasdaq Stock Market LLC
Warrants, each warrant to purchase one share of Common Stock	SXTPW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On March 20, 2026, the Company determined that an error was made in the calculation of the number of shares of common stock beneficially owned by an affiliate of the Company, which was disclosed in the Company’s prospectus supplement dated March 13, 2026 (the “Prospectus Supplement”).

Specifically, the number of shares beneficially owned by such affiliate was incorrectly reported as 21,490 shares. The correct number of shares beneficially owned by such affiliate is 23,367 shares.

The error resulted from an incorrect total share amount reported in a Form 4 filed on September 15, 2025, which was subsequently carried forward into later filings, including a Form 4 filed on December 16, 2025, and ultimately into the Prospectus Supplement. The corrected total number of shares beneficially owned by the affiliate is 16,781 shares, rather than 15,905 shares (as previously reported, after giving effect to the 1-for-4 reverse stock split).

The Company is filing this Current Report on Form 8-K to correct the disclosure contained in the Prospectus Supplement. Except as described above, no other information in the Prospectus Supplement is affected by this correction.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	60 DEGREES PHARMACEUTICALS, INC.

Date: March 20, 2026	By:	/s/ Geoffrey Dow
	Name:	Geoffrey Dow
	Title:	Chief Executive Officer and President

Source: View Original Filing on SEC EDGAR

FAQ

What did 60 Degrees Pharmaceuticals (SXTP) disclose in this Form 8-K?

60 Degrees Pharmaceuticals filed a Form 8-K to correct an error in the reported number of shares beneficially owned by an affiliate in a March 13, 2026 prospectus supplement, clarifying the accurate ownership figures without changing any other prospectus information.

What caused the ownership disclosure error identified by 60 Degrees Pharmaceuticals (SXTP)?

The company explains the error arose from an incorrect total share amount reported in a Form 4 filed on September 15, 2025, which was then carried forward into a later Form 4 on December 16, 2025 and into the March 13, 2026 prospectus supplement.

Does the SXTP correction affect any other information in the prospectus supplement?

The company states that, apart from correcting the affiliate’s beneficial ownership figures, no other information in the March 13, 2026 prospectus supplement is affected, indicating the change is limited to this specific share-count disclosure.

Filing Exhibits & Attachments

4 documents